Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of the Clinical,Serological and Genetic Factors That Determine Primary Non-response, Loss of Response and Adverse Drug Reactions to Anti-TNF Drugs in Patients With Active Luminal Crohn's Disease

Next Previous
X
Search
Trial Profile

Investigation of the Clinical,Serological and Genetic Factors That Determine Primary Non-response, Loss of Response and Adverse Drug Reactions to Anti-TNF Drugs in Patients With Active Luminal Crohn's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Adalimumab
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms PANTS

    • Most Recent Events

    • 07 Apr 2020 Results (n=1240) of extensive analysis exploring the cohort at 4D resolution and determining whether extended haplotypes considered as individual factors were published in the Gastroenterology
    • 05 Oct 2019 Results identifying variants associated with time to development of anti-drug antibodies in a discovery cohort of 1240 biologic naive patients with chron's disease published in the Gastroenterology
    • 20 Feb 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top